<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810964</url>
  </required_header>
  <id_info>
    <org_study_id>SMRI/SPHS: 2016-01</org_study_id>
    <nct_id>NCT02810964</nct_id>
  </id_info>
  <brief_title>Sulforaphane to Reduce Symptoms of Schizophrenia</brief_title>
  <official_title>A Double-Blind Placebo-Controlled Trial of a Sulforaphane Nutraceutical to Reduce the Symptoms of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheppard Pratt Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheppard Pratt Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if taking a sulforaphane nutraceutical versus a&#xD;
      placebo will reduce symptoms of schizophrenia when used in addition to standard antipsychotic&#xD;
      medications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Actual">November 11, 2019</completion_date>
  <primary_completion_date type="Actual">November 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase</measure>
    <time_frame>16 weeks (week 2 to week 18)</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in MATRICS Consensus Cognitive Battery (MCCB) Overall Composite Scores From the Start to the End of the Study</measure>
    <time_frame>18 weeks (week 0 to week 18)</time_frame>
    <description>The MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB) is a standardized battery of 10 tests that measure 7 domains of cognitive performance: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Overall composite t-scores are calculated using scores from all subtests. A t-score of 50 (10) is the mean (standard deviation) of the relevant reference population. Higher values indicate better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-Reactive Protein From the Start to the End of the Study</measure>
    <time_frame>18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pentraxin-3 From the Start to the End of the Study</measure>
    <time_frame>18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anti-Saccharomyces Cerevisiae IgA Class Antibodies From the Start to the End of the Study</measure>
    <time_frame>18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-6 From the Start to the End of the Study</measure>
    <time_frame>18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tumor Necrosis Factor - Alpha From the Start to the End of the Study</measure>
    <time_frame>18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interferon Gamma From the Start to the End of the Study</measure>
    <time_frame>18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Sulforaphane Nutraceutical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The sulforaphane nutraceutical contains inactive glucoraphanin, a glucosinolate from broccoli seeds, and myrosinase from broccoli sprouts. The ingestion of this compound leads to the hydrolysis of glucoraphanin, the generation of sulforaphane within the gastrointestinal (GI) tract, and the subsequent systemic absorption of the sulforaphane. The dose per tablet is 16 mg of glucoraphanin or 37 µmol; 6 tablets per day should yield about 100 µmol of sulforaphane. The tablets, which will be swallowed, are provided as .375 punch size, round concave tablets. In this arm, the participant will take 6 tablets of the sulforaphane nutraceutical daily for 16 weeks after a 2-week placebo run-in.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Identical-appearing Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The inert compound placebo looks identical to the sulforaphane nutraceutical. In this arm, the participant will take 6 tablets of the placebo daily for 16 weeks after a 2-week placebo run-in.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulforaphane Nutraceutical</intervention_name>
    <description>Sulforaphane Nutraceutical 6 tablets by mouth daily</description>
    <arm_group_label>Sulforaphane Nutraceutical</arm_group_label>
    <other_name>Avmacol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Identical-appearing Placebo</intervention_name>
    <description>Identical-appearing Placebo 6 tablets by mouth daily</description>
    <arm_group_label>Identical-appearing Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capacity for written informed consent&#xD;
&#xD;
          -  Age 18-65 years, inclusive&#xD;
&#xD;
          -  Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnosis&#xD;
             of schizophrenia or schizoaffective disorder as determined by the Structured Clinical&#xD;
             Interview for DSM-5 Disorders (SCID-5)&#xD;
&#xD;
          -  Currently an outpatient at time of screening&#xD;
&#xD;
          -  Residual psychotic symptoms of at least moderate severity as evidenced by a Positive&#xD;
             and Negative Syndrome Scale (PANSS) total score of 60 or higher AND one or more of the&#xD;
             following: one or more PANSS positive symptom scores of 4 or higher; OR containing at&#xD;
             least three positive or negative items with scores of 3 or higher at the screening&#xD;
             visit&#xD;
&#xD;
          -  Receiving antipsychotic medication for at least 8 weeks prior to enrolling in the&#xD;
             study with no antipsychotic medication changes within the previous 21 days from visit&#xD;
             2 (week 0)&#xD;
&#xD;
          -  Conformance to PORT Treatment Recommendation about Maintenance Antipsychotic&#xD;
             Medication Dose&#xD;
&#xD;
          -  Proficient in the English language&#xD;
&#xD;
          -  Participated previously in one of our screening studies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant or unstable medical disorder as determined by the principal&#xD;
             investigator and/or the study physician (e.g., HIV infection or other immunodeficiency&#xD;
             condition (such as receiving chemotherapy), uncontrolled diabetes, congestive heart&#xD;
             failure)&#xD;
&#xD;
          -  DSM-5 diagnosis of intellectual disability or comparable diagnoses determined by&#xD;
             previous versions of the DSM&#xD;
&#xD;
          -  DSM-5 diagnosis of a moderate or severe substance use disorder, except for caffeine or&#xD;
             tobacco, within the last three months prior to the screening visit. If the patient has&#xD;
             a positive drug toxicity screen at the time of visit 1 (screening), further evaluation&#xD;
             by the investigator will be done of the substance use to determine eligibility.&#xD;
&#xD;
          -  Any current use of a broccoli supplement (e.g., Avmacol® or other health food broccoli&#xD;
             supplement)&#xD;
&#xD;
          -  Participated in any investigational drug trial in the past 30 days prior to the&#xD;
             screening visit&#xD;
&#xD;
          -  Pregnant, planning to become pregnant, or breastfeeding during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faith Dickerson, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheppard Pratt Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheppart Pratt Health System</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <results_first_submitted>April 22, 2021</results_first_submitted>
  <results_first_submitted_qc>July 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2021</results_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheppard Pratt Health System</investigator_affiliation>
    <investigator_full_name>Faith Dickerson</investigator_full_name>
    <investigator_title>Principal Investigator, Stanley Research Program</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <keyword>Sulforaphane</keyword>
  <keyword>Sulforaphane supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforaphane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Demographic, symptom, and cognitive data will be shared with the National Database for Clinical Trials Related to Mental Illness (NDCT). Access may be obtained through an approved application with the NDCT.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02810964/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We enrolled n=64 participants drawn from rehabilitation and treatment programs in Central Maryland. Dates of recruitment: February 2017 - June 2019.</recruitment_details>
      <pre_assignment_details>We used a 2 week single-blind placebo phase for all participants prior to randomization. This placebo run-in was followed by the 16 week double-blind treatment phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sulforaphane Nutraceutical</title>
          <description>Sulforaphane nutraceutical 6 tablets by mouth daily for 16 weeks</description>
        </group>
        <group group_id="P2">
          <title>Identical-appearing Placebo</title>
          <description>Identical-appearing placebo 6 tablets by mouth daily for 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Placebo Run-In Phase (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Double-Blind Treatment Phase (16 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sulforaphane Nutraceutical</title>
          <description>Sulforaphane nutraceutical 6 tablets by mouth daily for 16 weeks</description>
        </group>
        <group group_id="B2">
          <title>Identical-appearing Placebo</title>
          <description>Identical-appearing placebo 6 tablets by mouth daily for 16 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="12.3"/>
                    <measurement group_id="B2" value="45.8" spread="11.7"/>
                    <measurement group_id="B3" value="44.2" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.</description>
        <time_frame>16 weeks (week 2 to week 18)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane Nutraceutical</title>
            <description>Sulforaphane nutraceutical 6 tablets by mouth daily for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Identical-appearing Placebo</title>
            <description>Identical-appearing placebo 6 tablets by mouth daily for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) measures psychiatric symptomatology, especially related to psychosis. The complete PANSS contains ratings for 30 symptoms, including 7 positive symptoms, 7 negative symptoms, and 16 general psychiatric symptoms. The severity of each symptom is rated on a scale ranging from 1 (minimal) to 7 (extreme); higher scores indicate increased symptomatology. Total PANSS scores include scores from all categories and range from 30 to 210 units on a scale.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 2 (Begin Treatment) PANSS Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" spread="12.2"/>
                    <measurement group_id="O2" value="81.5" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 18 (End Treatment) PANSS Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" spread="13.3"/>
                    <measurement group_id="O2" value="79.7" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in MATRICS Consensus Cognitive Battery (MCCB) Overall Composite Scores From the Start to the End of the Study</title>
        <description>The MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB) is a standardized battery of 10 tests that measure 7 domains of cognitive performance: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Overall composite t-scores are calculated using scores from all subtests. A t-score of 50 (10) is the mean (standard deviation) of the relevant reference population. Higher values indicate better performance.</description>
        <time_frame>18 weeks (week 0 to week 18)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane Nutraceutical</title>
            <description>Sulforaphane nutraceutical 6 tablets by mouth daily for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Identical-appearing Placebo</title>
            <description>Identical-appearing placebo 6 tablets by mouth daily for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MATRICS Consensus Cognitive Battery (MCCB) Overall Composite Scores From the Start to the End of the Study</title>
          <description>The MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB) is a standardized battery of 10 tests that measure 7 domains of cognitive performance: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Overall composite t-scores are calculated using scores from all subtests. A t-score of 50 (10) is the mean (standard deviation) of the relevant reference population. Higher values indicate better performance.</description>
          <units>t scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 0 (Baseline) MCCB Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="12.0"/>
                    <measurement group_id="O2" value="19.5" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 18 (End Treatment) MCCB Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" spread="12.6"/>
                    <measurement group_id="O2" value="22.8" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-Reactive Protein From the Start to the End of the Study</title>
        <time_frame>18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane Nutraceutical</title>
            <description>Sulforaphane nutraceutical 6 tablets by mouth daily for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Identical-appearing Placebo</title>
            <description>Identical-appearing placebo 6 tablets by mouth daily for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-Reactive Protein From the Start to the End of the Study</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CRP (Wk 0, Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10402.8" spread="13488.2"/>
                    <measurement group_id="O2" value="8969.7" spread="9021.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP (Wk 18, End Treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10198.5" spread="12110.9"/>
                    <measurement group_id="O2" value="10224.5" spread="13654.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pentraxin-3 From the Start to the End of the Study</title>
        <time_frame>18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane Nutraceutical</title>
            <description>Sulforaphane nutraceutical 6 tablets by mouth daily for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Identical-appearing Placebo</title>
            <description>Identical-appearing placebo 6 tablets by mouth daily for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pentraxin-3 From the Start to the End of the Study</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pentraxin(Wk 0, Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.414" spread="0.534"/>
                    <measurement group_id="O2" value="0.461" spread="0.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pentraxin (Wk 18, End Treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.394" spread="0.569"/>
                    <measurement group_id="O2" value="0.558" spread="0.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Anti-Saccharomyces Cerevisiae IgA Class Antibodies From the Start to the End of the Study</title>
        <time_frame>18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane Nutraceutical</title>
            <description>Sulforaphane nutraceutical 6 tablets by mouth daily for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Identical-appearing Placebo</title>
            <description>Identical-appearing placebo 6 tablets by mouth daily for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Anti-Saccharomyces Cerevisiae IgA Class Antibodies From the Start to the End of the Study</title>
          <units>units/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ASCA IGA (Wk 0, Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.195" spread="0.222"/>
                    <measurement group_id="O2" value="0.168" spread="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASCA IGA (Wk 18, End Treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.226" spread="0.277"/>
                    <measurement group_id="O2" value="0.176" spread="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interleukin-6 From the Start to the End of the Study</title>
        <time_frame>18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane Nutraceutical</title>
            <description>Sulforaphane nutraceutical 6 tablets by mouth daily for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Identical-appearing Placebo</title>
            <description>Identical-appearing placebo 6 tablets by mouth daily for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin-6 From the Start to the End of the Study</title>
          <units>pg/m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-6 (Wk 0, Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.623" spread="0.247"/>
                    <measurement group_id="O2" value="0.704" spread="0.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 (Wk 18, End Treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.694" spread="0.288"/>
                    <measurement group_id="O2" value="0.673" spread="0.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tumor Necrosis Factor - Alpha From the Start to the End of the Study</title>
        <time_frame>18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane Nutraceutical</title>
            <description>Sulforaphane nutraceutical 6 tablets by mouth daily for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Identical-appearing Placebo</title>
            <description>Identical-appearing placebo 6 tablets by mouth daily for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tumor Necrosis Factor - Alpha From the Start to the End of the Study</title>
          <units>pg/m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TNF-a (Wk 0, Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.668" spread="0.393"/>
                    <measurement group_id="O2" value="0.538" spread="0.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-a (Wk 18, End Treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.638" spread="0.362"/>
                    <measurement group_id="O2" value="0.520" spread="0.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Interferon Gamma From the Start to the End of the Study</title>
        <time_frame>18 weeks (assessed at weeks 0, 10, and 18; weeks 0 and 18 reported)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulforaphane Nutraceutical</title>
            <description>Sulforaphane nutraceutical 6 tablets by mouth daily for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Identical-appearing Placebo</title>
            <description>Identical-appearing placebo 6 tablets by mouth daily for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interferon Gamma From the Start to the End of the Study</title>
          <units>pg/m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFN-g (Wk 0, Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.514" spread="0.432"/>
                    <measurement group_id="O2" value="0.456" spread="0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-g (Wk 18, End Treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.478" spread="0.335"/>
                    <measurement group_id="O2" value="0.526" spread="0.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over an 18 week period, including the 2 week placebo run-in and the 16 week double-blind treatment phase.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sulforaphane Nutraceutical</title>
          <description>Sulforaphane nutraceutical 6 tablets by mouth daily for 16 weeks</description>
        </group>
        <group group_id="E2">
          <title>Identical-appearing Placebo</title>
          <description>Identical-appearing placebo 6 tablets by mouth daily for 16 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia exacerbation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematological symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine/metabolic symptoms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="32"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric symptoms</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory symptoms</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="32"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatological symptoms</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Faith Dickerson</name_or_title>
      <organization>Sheppard Pratt</organization>
      <phone>410-938-4359</phone>
      <email>fdickerson@sheppardpratt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

